Factors impacting antibody kinetics, including fever and vaccination intervals, in SARS-CoV-2-naïve adults receiving the first four mRNA COVID-19 vaccine doses.

To evaluate the antibody response following the initial four doses of mRNA vaccines (BNT162b2 or mRNA-1273) in SARS-CoV-2-naïve healthy adults and investigate factors influencing antibody titer increases, this prospective cohort study was conducted in Japan from March 2021. The study included participants who received either the 1st and 2nd doses (n = 467), 3rd dose (n = 157), or 4th dose (n = 89). Blood samples were collected before and up to 6 months after each dose, and anti-receptor-binding domain antibody levels were measured. Multivariate analysis (usin multiple linear regression or linear mixed models) revealed several factors significantly associated with higher post-vaccination antibody levels, including mRNA-1273 vaccine (after the 1st and 2nd dose), male gender (after the 3rd and 4th doses), younger age (after the 1st and 2nd dose), non-smoking status (after the 2nd dose), non-use of immunosuppressive agents (after the 1st dose), higher pre-vaccination antibody titers (after the 2nd, 3rd, and 4th doses), and higher post-vaccination fever (after the 2nd and 4th doses). Furthermore, longer intervals since the last dose were significantly associated with higher antibody levels after the 3rd and 4th doses. These findings provide valuable insights for optimizing vaccination strategies.

Hexavalent Cr ion adsorption and desorption behaviour of expanded poly(tetrafluoro)ethylene films grafted with 2-(dimethylamino)ethyl methacrylate.

A new polymeric adsorbent for Cr(VI) ions based on an expanded poly(tetrafluoroethylene) (ePTFE) film was prepared by the combined use of the pretreatment with oxygen plasma and photografting of 2-(dimethylamino)ethyl methacrylate (DMAEMA). The grafting of DMAEMA was characterized by XPS and FT-IR spectroscopic measurements. The adsorption behaviour of DMAEMA-grafted ePTFE (ePTFE-g-PDMAEMA) films was investigated as a function of the experimental parameters, such as the initial pH value, temperature, and grafted amount. The adsorption capacity and initial adsorption rate had the maximum values at the initial pH value of 3.0. On the other hand, the adsorption capacity became almost constant at temperatures higher than 30°C, although the adsorption rate increased over the temperature. The adsorption behaviour obeyed the pseudo-second-order kinetic model and well expressed by the Langmuir isotherm equation with higher correlation coefficients. These results indicate that the adsorption of Cr(VI) ions occurs through the electrostatic interaction between protonated dimethylamino groups on a grafted PDMAEMA chain and HCrO4- ions. Cr(VI) ions were successfully desorbed from Cr(VI)-loaded ePTFE-g-PDMAEMA films in the eluents, such as NaCl at 0.50 M, NH4Cl at 0.50M, and NaOH at 1.0 mM, and ePTFE-g-PDMAEMA films were repeatedly used for adsorption of Cr(VI) ions without appreciable loss in the adsorption capacity. It should be noted that Cr(VI) ion adsorptivity with a high initial rate was conferred to the ePTFE films. The results obtained in this study emphasize that ePTFE-g-PDMAEMA films can be applied as an adsorbent for Cr(VI) ions.

[Analysis of factors affecting the duration of treatment with sorafenib in patients with hepatocellular carcinoma].

The current status of treatment with sorafenib, and factors affecting the duration of treatment in patients started on sorafenib for hepatocellular carcinoma from July 2009 until April 2011 in the Department of Gastroenterology at Kobe City Medical Center General Hospital, were examined. Of 21 patients, 12 were able to continue the administration of sorafenib for more than one month, but 9 had to be discontinued within one month due to disease progression, worsening of general condition, and severe adverse reactions. In the group that was discontinued early, the rate of discontinuation due to side effects such as general fatigue, diarrhea, and hepatic encephalopathy was higher than in the long-term treatment group. On the other hand, hand-foot syndrome developed only in one case in both groups. The median value of PIVKA- II at the start of treatment in the long-term and early discontinued treatment groups were 672.5 and 14, 203 mAU/mL, respectively, and the values in the long-term group were significantly lower than those in the early-discontinued group (p < 0.05). From these results, the values of PIVKA-II at the start of sorafenib were considered to be factors affecting the continuation of sorafenib treatment. In addition, the dosing period was considered to be extended to focus on measures to take against the side effects of sorafenib within the early phase. Therefore, it was considered that these factors improved the effect of treatment with sorafenib in patients with hepatocellular carcinoma.

[Safety of pemetrexed mono-therapy in elderly patients with non-small cell lung cancer].

Safety of pemetrexed mono-therapy in elderly patients with non-small-cell lung cancer was examined between May 2009 and April 2010 at Kobe City Medical Center General Hospital . The numbers of non-elderly and elderly(over 70 years old)patients were 14 and 19, respectively. Rates of neutropenia over Grade 3 were 14. 3% in the non-elderly group, and 36. 8% in the elderly group(p=0. 297). However, febrile neutropenia was only seen in one case in each group(p=0. 606), and no treatment-related death was observed. Although the rates of rash appearance were 28. 6% and 36. 8%(p=0. 347)for the non-elderly and the elderly, respectively, most rashes were relieved by steroids. From these results, pemetrexed mono-therapy is considered one of the applicable regimens for elderly patients.